Four new 2-(2-piperidinoethyl)benzocycloalkanone derivatives, 20-23, were prepared and evaluated as potential antipsychotic agents in receptor binding assays for dopamine (DA) and 5-HTu receptors and in functional and behavioral screens. Their affinities for D2 receptors (Ki's in the nanomolar range: 46.7-70.7) and D1 receptors (Ki's in the micromolar range: 1.09-2.81) were slightly lower than that showed by haloperidol (Ki's in the nanomolar range: 5.01 and 97.72 for D2 and for D1 receptors, respectively). The ratio of pKi's values D1/D2 showed that the new molecules are more Dz-selective than haloperidol. In contrast, in the L3H1-ketanserin binding assays the new compounds had greater affinity for 5-HTu receptors (pKi's 7.89-8.60) than haloperidol (pKi 7.70) and in functional studies, endothelium-stripped aorta rings, the p A 2 values (6.75-8.12) were slightly lower than that of ketanserin (8.87) in suppresing serotonin-induced contractions. The pKi's for D2 binding (and to a lesser extent pKi's for D1 binding) tend to be greater among typical (classical) than among atypical antipsychotics, while these two classes of antipsychotics exhibit no difference with regard to pKi's for 5-HTu receptors. The ratios of pK;s for 5-HTzpJD2 receptors may be useful for rapid screening of new compounds, and its potential induction of extrapyramidal symptoms (ratio values > 1.12 were predictive of an atypical antipsychotic profile). The new molecules had a ratio value in the range 1.08-1.20, while haloperidol showed a ratio of 0.93. In the behavioral screening tests, the new molecules showed antagonist activity of amphetamine-inducing hyperactivity and apomorphineinduced climbing (predictive tests for antipsychotic activity). In the catalepsy test (predictive test for induction of extrapyramidal symptoms), the values obtained were in accordance with an atypical antipsychotic drugs profile.
Introduction
Administration of neuroleptics such as chlorpromazine or haloperidol is still the only effective treatment of a variety of psychiatric disorders (schizophrenia, the manic phase of manic-depressive psychosis). However, most neuroleptics (also called "classical antipsychotics") have two major drawbacks. First, they can induce extrapyramidal symptoms (sometimes at the start of treatment or following monthdyears of therapy). Second, negative symptoms (such as blunted affectivity, emotional withdrawal, apathy, and motor retardation) respond poorly in most patients. Since the 1970s, atypical (nonclassical) antipsychotics which have no extrapyramidal side effects and are effective against negative symptoms have been available. The prototype of this group, clozapine, whose atypical activity has been + This paper has been presented, in part, to the XIIth International Symposium on Medicinal Chemistry, Base1 (Switzerland), Sept 92 (Proceedings volume p 178).
attributed classically to its anticholinergic activity, was withdrawn because of its ability to induce agranulocytosis, but in view of the lack of alternatives has since been reintroduced into clinical practice, with the restriction that its use must be accompanied by rigorous blood monitoring. [1] [2] [3] Seeman4-6 reported that antipsychotic activity is closely correlated with the ability to block D2 dopamine receptors but not with D1 receptor blockade, although the subsequent development of D1-selective agonists and antagonists indicated that D1 receptors may also be involved in the clinical response to antipsychoti~s.~-~ For 10 years or more, the two subtype classification could accommodate most of the activities attributed to the dopaminergic system. However, this has changed and the dopamine receptors have been reviewed recently.lOJ1 Molecular cloning techniques have permitted the identification of several dopamine receptors called D1, D2 ( D~L and Dzs), D3, D4, and D~/ D~B , recently grouped together into two subfamilies: D1-like ( D~A and D&B) and D2-like (D2, D3 and D4) subfamilies.
The D1-like receptors exhibit very similar ligand binding properties: high affinity for benzazepines (SCH 23390, SKF 38393) and low affinity for butyrophenones (spiperone, haloperidol) and substituted benzamides (sulpiride). An interesting difference between the D1-like receptors is that the D~/ D~B receptor binds dopamine with a higher affinity than does the D~A receptor. All three D2-like receptors possess high affinity for butyrophenones such as spiperone and haloperidol and low affinity for benzazepines such as SKF 38393. The D4 receptor exhibits relatively high affinity for the atypical neuroleptic clozapine; this has led to speculation that the D4 receptor might be the relevant target of this atypical neuroleptic (for a review of DA receptors, see ref 12 and 13) .
Clozapine blocks not only dopamine receptors but also 5-HTu serotonin receptors, and recent findings suggest that its atypical activity may be due to this latter feature.14 This hypothesis is supported by clinical evidence that the 5-HTu-blocking capacity of certain antipsychotics reduces extrapyramidal side effects and improves the outcome of negative symptoms. An example is setoperone, a drug with potent 5-HTu-blocking and moderate D2-blocking activity which has proved effective in the treatment of negative symptoms in schizophrenics and also causes few extrapyramidal effects. l5 In previous papers16J7 we have reported the synthesis and antidopaminergic and antiserotoninergic activities of 34 aminomethy1)tetralones 1-3, which are conformationally restricted butyrophenone structures analogous to haloperidol, 4. As a continuation of that work we have now prepared the 2-(2-aminoethyl)benzocycloalkanones 20-23, which also possess the essential requirements for interaction with DA and serotonin (5-HT) receptors. These compounds have two butyrophenone pharmacophores, the (aminoethy1)cycloalkanone moiety and the 4-(p-fluorobenzoyl)piperidine fragment. This latter, which has been described as a neuroleptic pharmacophore of similar potency to the butyrophenone portion,18 is also an important feature for 5-HTu binding.lg
On the other hand, it is known that ketanserin 5 is the prototypic 5-HTu receptor antagonist. In the ketanserin molecule is necessary to consider two structural aspects: (a) the quinazolinone moiety is not essential and may be replaced by a pyrimido pyrimidine (e.g., pirenperone 6) or a thienopyrimidine nucleus (e.g., setoperone 7 ) or abbreviated to a simpler structural aroyl ketone or amide and (b) there is an aromatic binding site that accommodates the aryl portion of the heterocyclic ring.lg It is evident that the design of molecules under study satisfy these requirements because they have an aroyl portion that binds the pfluorobenzoyl fragment across an aminoethyl side chain partially incorporated in a conformationally restricted cycloalkanone structure.
Chemistry
Compounds 20-23 were synthesized via the sequence of reactions outlined in Scheme 1. Literature procedures for the preparation of tetralone-and indanoneacetic acids involve condensation with glyoxylic acid in alkaline medium and subsequent reduction with zinc and acetic acid of the resulting alkene acid.20i21 Other synthetic routes have been described for preparing these compounds. [22] [23] [24] [25] [26] In this paper, indanone, 5-fluoroindanone, tetralone, and benzosuberone-2-acetic acids 12-16 were prepared by one of the following methods: (A) aldol condensation with glyoxylic acid in alkaline medium to give l-oxo-2,3-dihydro-indanylidene acetic acid 8 and their 5-flUOrO derivative 9, (l-oxo-l,2,3,4-tetrahydro-2-naphthylidene)-acetic acid 10, and (l-oxo-1,2,3,4-tetrahydr0-5H-2-benzocyclohepteny1idene)acetic acid 11 in variable yields and (B) thermal condensation with glyoxylic acid at 160 "C in quantitative yields (Table 1) . Subsequent reduction of the alkene acids with zinc and acetic acid gave the saturated acids 12-16 also in quantitative yields (Table 2) . l-lktralone-2-acetic acid, 12, was also prepared with an overall yield of 75% by hydrolysis of the by reaction of the acid chlorides with P(p-fluorobenzoy1)-piperidine (route A) or by direct acid amine coupling with carboxylate activation by dicyclohexylcarbodde in the presence of 1-hydroxybenzotriazole (HOBt) (route B). Ketalization of both the carbonyl groups with ethylene glycol and p-TsOH in toluene gave the bis-(ethylene ketals) with variable yields. Later, lithium aluminum hydride reduction and subsequent deketalization then afforded to the amino ketones 20-23 in good to excellents yields ( Table 4) . Table 5) . pKis for Dz binding (and to a lesser extent pK{s for D1 binding) tend to be greater among typical (classical) than atypical antipsychotics, whereas these two classes of antipsychotic exhibit no difference as regards pK{s The new compounds were also tested for activity against amphetamine-induced hyperactivity at doses which had caused at least 75% inhibition of SMA 60 min after their administration. Haloperidol (ED50 = 0.098 mgkg ip) or compound 21 at dosages of 0.5 mgkg, 23 at 0.5 or 2 mgkg, and 20 or 22 at 8 mgkg all inhibited Apomorphine-induced climbing was strongly inhibited by haloperidol (ED50 = 0.15 mgkg ip) and by all the new compounds at the highest dose used (Figure 6 ). If it is assumed, following Ferris et al.,30 that climbing is caused by activation of limbic dopamine receptors, and since antipsychotic activity is the result of blockade of DA receptors in the limbic system, then these results suggest that the compounds tested can be classified as antipsychotics.
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The potency of the compounds under study to inhibit spontaneous locomotor activity, amphetamine-induced hyperactivity, and apomorphine induced climbing (at the highest dose used) was similar. Thus, the indanone derivative 21 was the most potent in reducing all behaviors, followed by the benzosuberone 23, being the least potent 20, analogue of 21, but lacking a fluorine atom in position 5, and 22, bearing a tetralone moiety.
Differences in the affinity for either D1 or D2 receptors cannot account for the relative potencies of the compounds, since their K{s were almost identical. It appears that the existence of two complete butyrophenone groups, such as in 21, is necessary to show a similar profile to haloperidol in behavioral tests.
Certain experimental results suggest that D2 selectivity may be a sign that a drug will induce catalepsy in experimental animals (and hence that it may cause extrapyramidal symptoms in human being^).^^^^^ Since our binding results showed that all the new substances are more D2 selective than haloperidol, we hypothesized that they would be more cataleptogenic than haloperidol in vivo. Somewhat to our surprise, this was not so. Whereas haloperidol, as expected, was markedly cataleptogenic (ED50 = 0.67 mgkg ip, confidence limits 0.5-0.9) and induced an average increase in position retention time of 28.8 s @ < 0.01) when the larger dose was used, the new compounds, in general, exhibited a much lower propensity to produce catalepsy. Compounds 20 and 22 produced, at dosages of 2-8 mgkg, a slight increase (no more than 5 s) in the time for which the imposed position was maintained and induced no catalepsy, while the molecules 21 and 23 (dosages of 0.5-8 mgkg) increased the time in initial imposed posture (in the range 10-20 s) and catalepsy was induced in only 13.3-33.3% and 6.7-16.7% of the tested animals, respectively; however, these percentages are much lower than those obtained with haloperidol ( Figure 7) . Furthermore, the effects of 21 and 23 in the catalepsy test differed qualitatively from those of haloperidol: whereas animals treated with the new molecules showed reduced muscle tone (appeared flaccid), the animals treated with haloperidol appeared rigid with high level of muscle tone.
Bruhwyler et al. 33 suggested that the induction of extrapyramidal symptoms by neuroleptics may be due to an imbalance between their effects on dopaminergic and cholinergic systems, and that atypical antipsychotics, such as clozapine, may lack extrapyramidal effects because they have both antidopaminergic and anticholinergic activity. To determine whether the weak cataleptogenic activity exhibited by our new compounds might be due to anticholinergic activity, we evaluated the protection they afforded against eserine (physostigminebinduced lethality. Since none of the new compounds afforded such protection, even at the highest dose used (results not shown), their weak cataleptogenic activity cannot, in fact, be attributed to concomitant anticholinergic activity.
Recent studies have suggested that 5-HT2~-blocking activity can reduce the cataleptogenic activity of neuroleptics while enhancing their antipsychotic activity.3,15,3* Setoperone and ritanserin, for example, both of which are more active as ~-H T~A blockers than as D2 blockers, have been reported to be more effective than selective DA receptors blockers in reducing the negative symptoms of schizophrenia and induce few extrapyramidal side effects. In view of such reports, other compounds with both 5-HTu-blocking and D2-blocking activity have also been developed. 35 According to the binding studies the new compounds interacted with both D1 and D2 receptors like haloperidol, although they had less affinity. However, they were slightly more D2 selective compared to haloperidol, as shown by the D1/D2 ratio. In contrast, all the new molecules displayed higher affinity for 5-HTu receptors than haloperidol. Interestingly, in this case the relative affinity for serotonin receptors appears to be related to the chemical structure of the compounds. 21 and 20, both bearing an indanone moiety, but the latter lacking the fluorine atom, showed the highest affinity for 5-HTu; the compound having a tetralone fragment (22) exhibited an affinity slightly lower, while 23 with the least affinity bore a benzosuberone. In summary, increasing the size of the ring which bears the carbonyl group diminishes the affinity for serotonin receptors.
In keeping with the above hypotheses regarding the combination of 5-HTu-blocking and D2-blocking activities, Meltzer et al. 28, 29 suggested that atypical antipsychotic drugs might be characterized by having a pK, ~-H T~A / D~ ratio no smaller than 1.12. The pKi 5 -H T d D1 and pKi ~-H T~A / D~ ratios of our new compounds were all greater than those of haloperidol; only 20 (hereafter designed as QF 0307B) and 21 (QF 0313B) have PKi ~-H T~A / D~ ratios strictly higher than 1.12, while 22 Structural fittings of X and Y fragments and the butyrophenone pharmacophore of haloperidol were performed by starting from their most stable conformations, superimposing the carbonyl groups, effecting torsions bringing the terminal nitrogen as close as possible to this of the template molecule, and then optimizing with these contraints. All the torsions affected only linear aliphatic chains and involved very little change in energy.
XI Xt
Fitting the butyrophenone pharmacophore of haloperidol to Y as above resulted in almost perfect overlap, with N atoms at only 0.09 A (Figure 9 ). Since both structures block dopamine receptors (see Pharmacology section), this suggests that the active conformation of haloperidol fragment may not be its minimum-energy conformation (Figure 9a ) but a more twisted for closer to Y (Figure 9b ). In this specific case, the energetic cost to acquire this final conformation is only 0.85 kcallmol; that it to say, nearly a free rotation. Following the same previously described procedure, the rigid 4-(pfluorobenzoyl)piperidine fragment (Y) was used as a template to which the three X fragments were fitted (Figure lo) . Since the goodness of the fit was unaffected by the size of the rings, and since all the X fragments appear to be pharmacologically effective, planarity of the aryl systems related to their size seems not to influence the dopamine-blocking activity of these structures. This finding contrasts with those of a parallel study of their 5-HT2~-blocking activity.27
Experiment a1 Sect ion
Chemistry. Melting points were determined with a Kofler hot-stage instrument or a Gallenkamp capillary melting points and are uncorrected. Infrared spectra were recorded with a Perkin-Elmer 1600 FTIR spectrophotometer; main bands are given in cm-l. Proton magnetic resonance spectra were obtained with a Brucker WM-250 (250 MHz) with tetramethylsilane as an internal standard. Mass spectra (FIB) were performed with a Kratos MS-50 mass spectrometer using 2-hydroxyethyl disulfide as a matrix. Elemental analyses were performed in a Perkin-Elmer 240B apparatus at the Microanalyses Service of the University of Santiago de Compostela (Spain); all reported values are within f0.4% of the theoretical compositions.
The general method of synthesis described are illustrative of those analogous compounds.
The progress of the reactions was monitored by the thinlayer chromatography.
1-0xo-1,2,3,4-tetrahydro-2-naphthylideneacetic Acid (10) ( monohydrate was heated in a Dean-Stark apparatus at 160 "C for 40-45 min. After cooling, the solid which formed was thoroughly triturated with ethyl acetate (2 x 50 mL). After filtration to separate undissolved materials, the liquid filtrate was washed several times with water and dried (Na2S04), and the solvent was evaporated to give 2.90 g (95%) of 10. A sample for analysis was obtained by recrystallization from EtOH. Mp: 188-190 "C. IR (KBr): 3400-2500 (OH), 1700 (COOH), 1670 (CO), 1640-1600 (C=C). 'H NMR (CDCl3) Oxo-1,2,3,4 -tetrahydro-2-naphthaleneacetic Acid (14) ( Table 2 ). 14 was prepared by reduction of 10 with zinc dust and acetic acid as previously described.38 Mp: 107-109 "C.
1-
The acetic acid 14 was also prepared by hydrolysis of the corresponding ethyl ester as indicated below.
A solution of 1.06 mL (7.5 mmol) of diisopropylamine in 40 mL of dried THF was cooled to -20 "C under N2 with stirring. n-Butyllithium (3.06 mL of a 2.5 M solution in n-CsH14; 7.5 mmol) was added, and stirring was continued for 0.5 h between -20 and -10 "C. The solution was then cooled to -70 "C and stirred 1 h more. A solution of 1.10 g (7.5 mmol) of a-tetralone in 8 mL of THF was added dropwise over 5-10 min. After 15 min at -70 "C the cooling bath was removed and the reaction mixture was allowed to warm to room temperature under N2 over 18 h. The THF was evaporated off, and the residue was dissolved in AcOEt/H2O. The solution was washed with 5% NaHC03 and 5% HC1 and dried (NazS04), and the AcOEt was evaporated off to give 1.71 g of crude product, which was purified by chromatography on silica gel with CH2C12 as eluent, yielding 1.34 g (77%) of the desired l-ox0-1,2,3,4- Table  2 ). Oxo-l,2,3,4-tetrahydro-2- Oxo-1,2,3,4-tetrahydro-2-naphthyl)acetyl]-4-@-fluorobenzoy1)piperidine (18) . Routek A solution of 1.91 g (22 mmol) of (p-fluorobenzoy1)piperidine in 30 mL of anhydrous toluene was slowly added to a stirred solution of 1.97 g (8.9 mmol) of acid chloride in 130 mL of anhydrous toluene under argon atmosphere. The resutling mixture was allowed to stir for 1 h and then heated under reflux for 24 h. After cooling, the solvent was removed under reduced pressure to give a brown oil which was dissolved in dichloromethane, the resulting solution washed with 10% NazC03 and HzO and dried (NaZSOd), and the solvent was removed in vacuo. The resulting orange oil was purifed by flash chromatography (silica gel, AcOEthexane, 1:l) to give 1.1 g (95%) of a yellow oil that does not crystallize on standing. Attempted Kugelrohr distillation caused decomposition. IR (film): 1715 (CO cycloalkanone), 1678 (CO benzoyl), 1643 (CO-N). The bis(2,4-dinitropheny1)hydrazone melted at 207-208 "C (AcOEt) (see Table 3 ).
l-
N-[(l-
Route B.
Under an argon atmosphere, a solution of 0.61 g (2.94 mmol) of 4-(p-fluorobenzoyl)piperidine, N-hydroxybenzotriazole (0.80 g, 5.88 mmol), and 0.60 g (2.94 mmol) of the acid 14 was stirred at room temperature for 1 h; 1.21 g (5.88 mmol) of NJV-dicyclohexylcarbodiimide was then added to the cooled mixture (0 "C) which was stirred at 0 "C for 1 h and then for 16 h at room temperature. After removal of the DMF in vacuo, the residue obtained was dissolved in CHzClz (150 mL), and the resulting solution was washed with 5% NaHC03 (2 x 25 mL) and HzO (2 x 40 mL) and dried (NaZSOd), and the solvent was removed under reduced pressure. The oil residue was purified by flash chromatography (silica gel, AcOEthexane 1:l) to give 0.94 g (81%) of a yellow oil that was identified by IR and as 2,4-dinitrophenylhydrazone, mp 207-208 "C (EtOH) (see Table 3 ). Oxo-1,2,3,4-tetrahydro-2-naphthyl)ethyl]-4-(pfluorobenzoy1) piperidine Bis(ethy1ene ketal). A stirred solution of 1.76 g (46 mmol) of the amide 18, 17.27 g (0.28 mmol) of ethylene glycol, and 54 mg of p-TsOH in 55 mL of anhydrous toluene was refluxed in a Dean-Stark apparatus for 22.5 h with azeotropic distillation of water. After cooling, the toluene solution was washed with 10% NazC03 (2 x 30 mL) and HzO (2 x 30 mL) and dried (Na2S04), and the solvent was removed under reduced pressure. The resulting crude bisketal (2.05 g, 95%) was an orange oil with only one 1R band (1650, CO-N) and was used in the next step without further purification. thoroughly washed with ether. The combined filtrates were treated with 10% HC1 and stirred vigorously at 35-40 "C for 1 h. On cooling, the aqueous layer was made alkaline with 10% NaOH and extracted with ether (3 x 50 mL), the combined ether extracts were dried (NazSOJ, and the solvent was partially removed under reduced pressure. ' Ib the resulting concentrated solution was cautiously added ether-saturated HC1 gas. The white precipitate that formed was recovered and kept overnight in a vacuum desiccator; recrystallization from MeOH afforded 0.61 g (85%) of white crystals. 25 g ), and male Sprague-Dawley rats (275 f 25 g) were used. "In vivo" assays was carried out in a quiet room thermostated at 22 f 1 "C with a 12-h lighudark cycle (08.00-20.00) and always at the same time of day (so as to avoid variation due to circadian rhythms). Food and tap water were free available in the home cage. Aorta Ring Experiments. Endothelium-stripped aorta rings from Sprague-Dawley rats were mounted under a resting tension of 1.5 gin a 20-mL organ bath containing Krebs solution (composition (mM): NaC1, 118.07; KC1,4; CaC12H20, 2.5; MgSOs7Hz0, 1.2; KHzPO4, 1.2; NaHC03,25; glucose, 11) at 37 "C bubbled with carbogen (95% 0 2 , 5 % COz). Isometric contraction forces were measured using a CPUL 0-25-g transducer connected to a Celaster 10s-1 apparatus. After stabilization for 60 min, cumulative concentration-response curves were constructed as per Van Rossum,4O increasing serotonin concentrations from 30 nM to 10 mM in the absence or in the presence of increasing concentrations of ketanserine or new compounds. 
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which was calculated from a Schild plot of log (dose ratio -1) for three antagonist concentrations; six replicate experiments were performed. Molecular Modeling. The geometries of molecular fragments were optimized by the AM1 method43 as implemented in the program MOPAC.44 For both these computations and structural fitting, the molecular modeling package BIOSYM Inc., San Diego, CA, was used.
